Keyphrases
Israel
100%
Human Immunodeficiency Virus Type 1 (HIV-1)
34%
Israeli
22%
HIV Patients
21%
Odds Ratio
21%
COVID-19
19%
Hospitalized Patients
18%
Risk Factors
18%
Methicillin-resistant Staphylococcus Aureus
17%
West Nile Fever
14%
Confidence Interval
14%
Bacteremia
13%
Virus
12%
Invasive Pneumococcal Disease
11%
Quinolones
10%
Antibiotic Use
10%
Antibiotics
10%
13-valent Pneumococcal Conjugate Vaccine (PCV13)
9%
Escherichia Coli
9%
Hospital Admission
9%
Nationwide Surveillance
9%
Viral Load
9%
Surgical Site Infection
9%
Clinical Characteristics
9%
Risk Behavior
8%
Antibiotic Resistance
7%
Hospitalization
7%
Infected Patients
7%
Ethiopian
7%
HIV-1 Subtype C
7%
HIV-positive
7%
Randomized Controlled Trial
7%
Empirical Therapy
7%
Antibiotic Treatment
6%
Encephalitis
6%
West Nile Virus Infection
6%
Comorbidity
6%
Vaccination
6%
30-day Mortality
6%
Virological Failure
6%
Men Who Have Sex with Men
6%
Retrospective Cohort Study
6%
Older Adults
6%
Oncology Patients
6%
Highly Active Antiretroviral Therapy (HAART)
6%
Surveillance Studies
6%
Bloodstream Infection
6%
PCV7
6%
Travellers
6%
Drug Resistance
6%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
27%
Bloodstream Infection
26%
Infection
24%
Cohort Study
22%
Diseases
21%
Antiinfective Agent
14%
Pneumococcal Infection
11%
Methicillin-Resistant Staphylococcus Aureus
9%
Quinolone Derivative
9%
Prevalence
8%
West Nile Fever
8%
Rituximab
8%
Randomized Controlled Trial
8%
Antibiotics
8%
Antimicrobial Resistance
6%
Ciprofloxacin
6%
Hematologic Malignancy
6%
Pneumococcus Vaccine
6%
Penicillin
6%
Streptococcus pneumonia
6%
Combination Therapy
5%
2009 H1N1 Influenza
5%
Pneumocystis Jiroveci
5%
Coronavirinae
5%
SARS Coronavirus
5%
Enterobacteriaceae
5%
Aztreonam
5%
Escherichia coli
5%
Piperacillin Plus Tazobactam
5%
Quinolone
5%
Gentamicin
5%
Antibiotic Therapy
5%
Amoxicillin
5%
Clavulanic Acid
5%
Mortality Rate
5%
Adverse Event
5%
Comorbidity
5%
Medicine and Dentistry
Human Immunodeficiency Virus
40%
Bloodstream Infection
16%
Infection
15%
COVID-19
14%
Drug Resistance
12%
Cohort Analysis
12%
West Nile Fever
11%
Diseases
11%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Antibiotic Therapy
9%
Antiretroviral Therapy
9%
Surgical Infection
8%
Pneumococcal Infection
8%
Rituximab
8%
West Nile Virus
8%
Mortality Rate
8%
Prevalence
8%
Virus Infection
8%
Odds Ratio
7%
Omicron Coronavirus Variant
6%
Resistance Mutation
6%
Virus
6%
Encephalitis
5%
Pneumocystis Jirovecii
5%
Enterobacteriaceae
5%
Human Immunodeficiency Virus Infection
5%
Combination Therapy
5%
High Risk Behavior
5%
Comorbidity
5%
Extended Spectrum Beta Lactamase
5%
Serotype
5%
Nonnucleoside Reverse Transcriptase Inhibitor
5%
Hematologic Malignancy
5%
